Bit & Bridle

Equine Cutaneous Lymphosarcoma

Other Names

  • Equine Cutaneous Lymphoma
  • Epitheliotropic Lymphosarcoma
  • Cutaneous T-cell Lymphoma (equine)
  • Skin Lymphoma in Horses

What is Equine Cutaneous Lymphosarcoma?

Equine cutaneous lymphosarcoma is a malignant tumour of lymphocytes (a type of white blood cell) that primarily affects the skin. It is the most common site for lymphoma to manifest in horses, though lymphoma can also present with internal (multicentric) or gastrointestinal forms. Cutaneous lymphosarcoma involves the infiltration of neoplastic (cancerous) lymphocytes into the dermis and subdermis, producing nodular, plaquelike, or diffuse skin lesions across the body.

The condition tends to affect middle-aged to older horses, though it can occur at any age. It is not a common tumour, but it is one of the more frequently recognised forms of equine lymphoma encountered in practice. Because skin lesions are visible and accessible, cutaneous lymphosarcoma is often identified at an earlier stage than internal forms of lymphoma, which can have a more insidious presentation.

Understanding this condition is important for horse owners — the appearance of multiple skin nodules in a horse can have many causes, and biopsy is necessary for definitive diagnosis. Some cases respond to treatment, though long-term prognosis is generally guarded.

Causes

The exact cause of equine lymphosarcoma is not known. As in most cancers, it is likely multifactorial:

  • Immune dysregulation: Abnormal immune function may allow neoplastic lymphocytes to proliferate unchecked.
  • Viral factors: Retroviral involvement has been investigated in horses, as retroviruses cause lymphoma in other species, but no definitive equine lymphotropic virus has been established as a cause.
  • Age: The risk increases with age, consistent with the cumulative genetic mutations theory of cancer development.
  • Genetics and breed: Some breed predispositions have been suggested, though no strong breed-specific link has been confirmed for cutaneous lymphosarcoma specifically.
  • No contagion: Lymphosarcoma is not contagious between horses.

Symptoms and Signs

  • Multiple skin nodules: The most characteristic finding — multiple firm-to-soft nodules scattered across the body surface. Nodules are typically within or just under the skin (dermal or subcutaneous), range from a few millimetres to several centimetres in diameter, and may be solitary initially before becoming more numerous.
  • Distribution: Lesions may appear anywhere on the body, but the neck, trunk, and limbs are commonly involved. In some horses, lesions preferentially affect specific areas.
  • Plaques or diffuse thickening: Some cases present with flat, plaque-like lesions or widespread skin thickening rather than discrete nodules.
  • Alopecia (hair loss): Skin overlying lesions may show hair loss or changes in coat quality.
  • Pruritus (itching): Variable; some horses show moderate to severe itching, particularly with epitheliotropic (skin-infiltrating) forms.
  • Ulceration: Nodules may ulcerate and discharge in advanced cases.
  • Generalised signs: Weight loss, lethargy, reduced performance, oedema (particularly of the legs), and anaemia may develop as the disease progresses or involves other organs.
  • Lymph node enlargement: Regional or generalised lymphadenopathy (swollen lymph nodes) may be palpable.

Diagnosis

Definitive diagnosis requires histopathological examination of affected tissue:

  • Fine needle aspirate (FNA): A needle is passed into a nodule to collect cells for cytological examination. This is a quick, minimally invasive first step that can indicate the presence of neoplastic lymphocytes, but histopathology is needed for a definitive diagnosis.
  • Excisional or incisional biopsy: A tissue sample from a nodule is submitted for histopathological examination. The pathologist can characterise the type of lymphocyte involved (T-cell vs. B-cell) and confirm malignancy. This is the gold standard for diagnosis.
  • Immunohistochemistry: Further characterisation of the lymphocyte type (CD3 for T-cells, CD20 or CD79a for B-cells) using special stains on the biopsy sample provides important prognostic information. Epitheliotropic (T-cell) lymphomas tend to be more aggressive.
  • Haematology and biochemistry: Blood work may reveal anaemia, abnormal white cell populations (circulating lymphoma cells in some cases), hypoproteinaemia, or elevated globulins. Useful for staging and monitoring.
  • Staging: Ultrasound examination and, where available, CT can assess for internal organ involvement and lymph node enlargement, which is important for prognosis and treatment planning.

Treatment

Treatment options for equine cutaneous lymphosarcoma are limited but may provide periods of remission:

  • Corticosteroids: Oral prednisolone or dexamethasone can induce temporary remission in some horses — anti-inflammatory and lympholytic effects can reduce the size and number of lesions. Responses vary; some horses show significant improvement, while others do not respond. Long-term corticosteroid use carries its own risks, including laminitis.
  • Combination chemotherapy: Protocols adapted from small animal oncology (e.g., combinations of cyclophosphamide, vincristine, prednisolone — “COP” protocol) have been used in horses with variable results. Access to oncological expertise is required, and costs can be significant. Most practical in younger horses with early-stage disease.
  • Surgical excision: Rarely applicable — the multifocal nature of cutaneous lymphosarcoma makes complete surgical removal impractical in most cases. May be useful for solitary lesions.
  • Supportive care: Management of secondary complications — wound care for ulcerated lesions, nutritional support, treatment of oedema.
  • Palliative management: For horses where treatment is not elected or does not achieve remission, attention to quality of life — maintaining condition, managing pruritus, and monitoring comfort — is an important part of care.

Prevention

There are no specific preventive measures for equine cutaneous lymphosarcoma, as the aetiology is not fully understood:

  • Routine health monitoring and prompt veterinary assessment of any new or unusual skin lesions allows earlier diagnosis.
  • Maintaining good overall health — appropriate nutrition, parasite control, dental care, and vaccination — supports a healthy immune system.
  • Regular grooming and physical examination of the horse is the best way to detect early skin changes.

Prognosis

The prognosis for equine cutaneous lymphosarcoma is generally guarded to poor for long-term survival. The condition is malignant and tends to progress over months to years. However, the course is variable:

  • Some horses maintain acceptable quality of life for a year or more with or without treatment.
  • Cases that respond to corticosteroids or chemotherapy may achieve periods of remission ranging from months to occasionally years.
  • Epitheliotropic (T-cell) lymphoma tends to be more aggressive with a shorter survival time.
  • Horses with concurrent internal organ involvement (multicentric disease) have a significantly worse prognosis than those with purely cutaneous disease.
  • Euthanasia is appropriate when quality of life deteriorates due to widespread, ulcerated, painful lesions; severe pruritus; significant weight loss; or systemic illness that does not respond to treatment.

When to Call the Vet

Contact your vet if you notice:

  • Multiple new skin nodules appearing over a period of weeks to months
  • Skin lesions that are growing, ulcerating, or increasing in number
  • A horse losing weight alongside skin changes
  • Swollen lymph nodes under the jaw or in the flank region alongside skin changes
  • Severe unexplained itching alongside skin nodules or thickening

Frequently Asked Questions

Are equine skin nodules always lymphosarcoma?

No — equine skin nodules have many possible causes, the majority of which are not lymphosarcoma. Common differential diagnoses include equine sarcoids, melanomas (particularly in grey horses), mast cell tumours, eosinophilic granulomas, nodular collagenolytic granuloma (collagen necrosis), insect bite reactions, and dermatophytosis (ringworm). Biopsy and histopathology are essential to distinguish lymphosarcoma from these other conditions, as the appearance can overlap considerably. Do not assume any diagnosis without laboratory confirmation.

Can horses with cutaneous lymphosarcoma live comfortably?

In the early and intermediate stages, many horses with cutaneous lymphosarcoma maintain good quality of life and continue in light work. Regular monitoring, appropriate medical management, and attentive husbandry can keep affected horses comfortable for extended periods. The decision regarding treatment and the appropriate time to consider euthanasia should be made in close consultation with your vet, assessing the horse’s condition and quality of life on an ongoing basis.

Is equine lymphoma the same as lymphosarcoma?

The terms are used interchangeably in equine medicine. Technically, “lymphosarcoma” (or lymphosarcoma) refers to a malignant tumour of lymphocytes, while “lymphoma” can encompass both benign and malignant lymphoid tumours — but in horses, lymphoma is almost always malignant, and the terms are effectively synonymous in clinical practice. Both refer to the same family of neoplastic conditions involving lymphocyte proliferation.

What other forms of lymphoma can horses get?

Beyond the cutaneous form, horses can develop multicentric lymphoma (involving multiple internal lymph nodes and organs), gastrointestinal lymphoma (causing weight loss, malabsorption, and diarrhoea), mediastinal/thoracic lymphoma (causing respiratory signs and pleural effusion), and less commonly, splenic or hepatic lymphoma. Each form has a different presentation and prognosis. Cutaneous lymphosarcoma is generally one of the more favourable presentations in terms of initial detectability and, in some cases, treatability compared to internal forms.